APM
SLRN

Avidity Partners Management’s ACELYRIN SLRN Stock Holding History

Avidity Partners Management’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-750,000
Closed -$15.7M – 100
2023
Q2 		$15.7M Buy
+750,000
New +$15.3M 0.55% 62

Other funds holding SLRN

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Avidity Partners Management's SLRN Position: Q3 2023 in Review

Avidity Partners Management sold out of ACELYRIN (SLRN) in Q3 2023, closing a stake of 750,000 shares — an estimated $15.7M sold.

Avidity Partners Management first reported a position in SLRN in Q2 2023 and held it in 1 quarter. The position peaked at $15.7M in Q2 2023. 101 funds tracked by Wall St. Rank hold SLRN as of Q3 2023.

  • Avidity Partners Management reported no remaining ACELYRIN position as of Q3 2023 after selling out during the quarter.
  • Avidity Partners Management sold 750,000 ACELYRIN shares in Q3 2023, an estimated $15.7M.
  • Avidity Partners Management first reported a position in ACELYRIN in Q2 2023 and held it in 1 quarter.
  • Avidity Partners Management's ACELYRIN position peaked at $15.7M in Q2 2023.
  • 101 funds tracked by Wall St. Rank held ACELYRIN as of Q3 2023.

Based on Avidity Partners Management's 13F filing for Q3 2023, filed 14 Nov 2023.